Best Stocks To Invest In 2023


The National Football League (NFL) has barred its teams from selling sponsorships to cryptocurrency trading firms or NFTs, as it evaluates the cryptocurrency industry.  

According to the report, the league is developing an official strategy for crypto and NFTs and till then the suspensions remain in place. 

NFL’s 32 team members are prohibited from selling ads or sponsorships to crypto coins, crypto marketplaces, and other companies that sell blockchain assets, as well as releasing their own NFTs. 

The league now has a set of rules that significantly limit what teams can use cryptocurrency. 

According to leagues' new rules, teams can collaborate with crypto adjacent companies, but partnerships with those directly tied to crypto, such as exchanges, go against the new guidelines.

“The teams can get sponsorships from companies whose primary business is providing investment advisory and or fund management services in connection with cryptocurrency, provided that such advertising sponsorship rights are limited to promoting the company’s corporate brands,” the report says. 


NFL players are allowed to have crypto and blockchain company sponsorships. 

Tom Brady and top draft choice Trevor Lawrence both have deals with FTX. In addition, Brady launched his own NFT platform, Autograph, in August.

The NFL was the last major sports league in the USA to allow gambling and liquor sponsors.

Other leagues have moved further with digital assets. NBA Top Shot, created through a partnership between Dapper Labs and the NBA, has hosted $675 million in sales since its beta launch in May 2020. 

Also Read: 10 Most Valuable NFL Teams: How Media Rights And A Super Bowl Affected The 2021 List

Best Stocks To Invest In 2023: First Citizens BancShares, Inc.(FCNCA)


First Citizens BancShares, Inc. operates as the holding company for First-Citizens Bank & Trust Company that provides banking services to retail and commercial customers. Its deposit products include demand, checking, savings, and time deposits, as well as money market accounts. The company’s loan products portfolio comprises commercial construction and land development loans; commercial mortgage loans, commercial and industrial loans, and lease financing; other commercial real estate loans; revolving mortgage loans; consumer loans; and residential mortgage, and noncommercial construction and land development loans. It also offers treasury services products, cardholder and merchant services, wealth management services, and various other products and services; investment services, including annuities, discount brokerage services, and third-party mutual funds, as well as investment advisory services; and title insurance products. The company offers its products and services through its branch network, as well as through online banking, telephone banking, mobile banking, and various ATM networks. As of December 31, 2014, it operated 572 branches in Arizona, California, Colorado, Florida, Georgia, Kansas, Maryland, Missouri, New Mexico, North Carolina, Oklahoma, Oregon, South Carolina, Tennessee, Texas, Virginia, Washington, West Virginia, and the District of Columbia. The company was founded in 1898 and is headquartered in Raleigh, North Carolina.


Advisors’ Opinion:

  • [By Jon C. Ogg]

    Ardelyx Inc. (NASDAQ: ARDX) was started with a Buy rating at Jefferies on Friday, and the $7 price target compared with a $4.15 prior close. Its shares were up about 3% at $4.30 in the morning the call was made, and the market cap was roughly $265 million. Ardelyx also has a 52-week trading range of $3.58 to $8.65. While this may imply major upside of more than 60% if the analyst call proves correct, Leerink had resumed coverage on Ardelyx with an Outperform rating and a $13 price target back in March of 2018. Investors may want to keep in mind that Ardelyx sold $50 million worth of shares at $4.00 per share in May of this year. Jefferies and Leerink were the joint book-running managers for that offering.

  • [By Max Byerly]

    Connor Clark & Lunn Investment Management Ltd. raised its holdings in Ardelyx Inc (NASDAQ:ARDX) by 25.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 136,534 shares of the biopharmaceutical company’s stock after purchasing an additional 27,903 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Ardelyx were worth $505,000 as of its most recent SEC filing.

  • [By Shane Hupp]

    Ardelyx (NASDAQ: ARDX) and KITOV PHARMA LT/S (NASDAQ:KTOV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.

  • [By Max Byerly]

    Here are some of the news headlines that may have impacted Accern’s analysis:

    Get Ardelyx alerts:

    Short Interest in Ardelyx Inc (ARDX) Decreases By 55.8% (americanbankingnews.com) Key Aspects to Watch Out: Ardelyx, Inc. (ARDX) (connectinginvestor.com) What Analyst Recommend? Ardelyx, Inc. (ARDX) stock is worth at $ $3.95 (nasdaqfortune.com) Hot Stock to Track – Ardelyx Inc (NASDAQ: ARDX) (stocksmarketcap.com) Ardelyx, Inc. (ARDX) – Well known Mover to Watch (nasdaqfortune.com)


    Several analysts have commented on ARDX shares. ValuEngine raised Ardelyx from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 23rd. Zacks Investment Research lowered Ardelyx from a “hold” rating to a “sell” rating in a research note on Tuesday, March 20th. BidaskClub raised Ardelyx from a “sell” rating to a “hold” rating in a research report on Thursday, May 17th. Leerink Swann reissued an “outperform” rating and issued a $13.00 price objective on shares of Ardelyx in a research report on Monday, March 19th. Finally, Cantor Fitzgerald set a $12.00 target price on Ardelyx and gave the company a “buy” rating in a research note on Saturday, March 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Ardelyx presently has a consensus rating of “Buy” and a consensus price target of $13.08.

Best Stocks To Invest In 2023: Physicians Realty Trust(DOC)


Physicians Realty Trust, a self-managed healthcare real estate company, focuses on the acquisition, development, ownership, and management of healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems. The company’s portfolio would consists of 19 medical office buildings with approximately 528,048 net leasable square feet located in 10 states. It intends to elect and qualify to be taxed as a real estate investment trust for federal income tax purposes. The company was founded in 2013 and is based in Milwaukee, Wisconsin.


Advisors’ Opinion:

  • [By Money Morning News Team]

    Rounding out the top five is a financial services stock, Wheeler Real Estate Investment Trust Inc. (NASDAQ: WHLR), which advanced more than 63% to end the week at $1.80 per share.

  • [By Money Morning Staff Reports]

    Here are last week’s top-performing penny stocks:

    Penny Stock Sector Current Share Price Last Week’s Gain
    OncoCyte Corp. (NYSE: OCX) Healthcare $4.98 159.38%
    Fortress Biotech (NASDAQ: FBIO) Healthcare $2.47 133.02%
    Trevena Inc. (NASDAQ: TRVN) Healthcare $1.01 86.69%
    Celldex Therapeutics Inc. (NASDAQ: CLDX) Healthcare $0.58 66.82%
    Wheeler Real Estate Investment Trust Inc.(NASDAQ: WHLR) Financial $1.80 63.64%
    Scynexis Inc. (NASDAQ: SCYX) Healthcare $1.13 53.64%
    Eldorado Gold Corp. (NYSE: EGO) Basic Materials $3.98 47.96%
    Novus Therapeutics Inc. (NASDAQ: NVUS) Healthcare $4.15 43.60%
    PHI Inc. (NASDAQ: PHII) Services $4.50 42.14%
    BioTime Inc. (NYSE: BTX) Healthcare $1.33 41.50%

    See Now: Our founder just released his No. 1 pick for 2019. Don’t miss this. See urgent briefing here…

Leave a Reply

Your email address will not be published.